By Bingyan Wang

Nasdaq-listed 111 Inc. has started retail sales of Pfizer Inc.'s oral Covid-19 treatment pill in China, according to the healthcare platform's website.

The sales page on the Chinese platform on Tuesday showed it is now offering ​Paxlovid, the Covid-19 medication that Beijing approved in February, for customers with positive polymerase chain reaction or antigen test results.

Pfizer started manufacturing Paxlovid in 2021.

Paxlovid has been used by medical practitioners to treat patients in China since March, when Shanghai was hit by a Covid-19 outbreak, according to local media reports.

Write to Bingyan Wang at bingyan.wang@wsj.com

(END) Dow Jones Newswires

December 13, 2022 06:03 ET (11:03 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2024 まで 4 2024 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2023 まで 4 2024 Pfizerのチャートをもっと見るにはこちらをクリック